Department for Coagulation Disorders, Skåne University Hospital, University of Lund, Malmö, Sweden.
Thromb Res. 2011 Oct;128(4):341-5. doi: 10.1016/j.thromres.2011.04.022. Epub 2011 May 28.
Numerous associations between chronic kidney disease (CKD) and atrial fibrillation (AF) have been reported and patients with CKD on anticoagulation therapy have an increased risk of bleeding. Currently, new anticoagulant agents are emerging in clinical practice, some of which are excreted by the kidneys. The proportion of AF patients on anticoagulant treatment with reduced renal function is, however, unknown.
Using AURICULA, a Swedish registry for anticoagulation, estimated glomerular filtration rate (eGFR) was investigated in AF patients on warfarin treatment (n = 2,603). The study group was compared with a healthy sample from the population (n = 2,261). Two different creatinine prediction equations were used for calculating eGFR: the Lund-Malmö (LM) and MDRD Study equation.
The fraction of AF patients with eGFR <30 and <45 ml/min/1.73 m(2) were 8.1% and 22.9% with the LM and 4.3% and 16.3% with the MDRD equation, respectively, and significantly higher than corresponding values in the reference population. GFR decreased with increasing age, where 11.4% and 5.6% of AF patients aged ≥ 75 years had eGFR <30 ml/min/1.73 m(2) according to the LM and MDRD equations, respectively.
Severe renal impairment is common among AF patients on anticoagulant treatment with warfarin, especially at higher ages. Monitoring of renal function should be implemented in clinical practice for AF patients treated with new anticoagulants eliminated by the kidneys.
大量研究报道了慢性肾脏病(CKD)与心房颤动(AF)之间的诸多关联,接受抗凝治疗的 CKD 患者出血风险增加。目前,新的抗凝药物已在临床实践中应用,其中一些药物经肾脏排泄。然而,肾功能下降的 AF 患者接受抗凝治疗的比例尚不清楚。
利用瑞典抗凝登记处 AURICULA,对接受华法林治疗的 AF 患者(n = 2603)的估算肾小球滤过率(eGFR)进行了研究。将研究组与来自人群的健康样本(n = 2261)进行了比较。使用两种不同的肌酐预测方程计算 eGFR:隆德-马尔默(LM)和 MDRD 研究方程。
根据 LM 和 MDRD 方程,eGFR <30 和 <45 ml/min/1.73 m2 的 AF 患者比例分别为 8.1%和 22.9%,4.3%和 16.3%,明显高于参考人群的相应值。eGFR 随年龄增加而降低,根据 LM 和 MDRD 方程,年龄≥75 岁的 AF 患者中,分别有 11.4%和 5.6%的患者 eGFR <30 ml/min/1.73 m2。
接受华法林抗凝治疗的 AF 患者中严重肾功能不全较为常见,尤其是年龄较大的患者。对于经肾脏消除的新抗凝药物治疗的 AF 患者,应在临床实践中实施肾功能监测。